Immunoglobulin-G Human + Maltose

Welcome to Dwaey, specifically on Immunoglobulin-G Human + Maltose page.
This medicine contains important and useful components, as it consists of
Immunoglobulin-G Human + Maltose is available in the market in concentration.

Generic Name of Immunoglobulin-G Human + Maltose - Learn More

Immunoglobulin-G Human + Maltose

Immunoglobulin-G Human + Maltose Precaution - What You Need to Know

Before receiving Immunoglobulin-G Human + Maltose (IVIG with maltose), patients should consult their healthcare provider due to potential risks associated with its use. Key precautions include:

- Allergic Reactions: Patients who are allergic to any component of the product, particularly maltose, should not receive this treatment. An anaphylactic reaction may occur, so it's important to assess the risk before administration.
- Renal Health: Immunoglobulin-G (IgG) products can impact renal function, especially in patients with pre-existing renal impairment or those receiving high doses. It's essential to monitor kidney function, especially during prolonged or high-dose therapy. In some cases, dosage adjustments or discontinuation may be necessary.
- Hyperviscosity: This product can increase the viscosity of blood, leading to thrombosis (blood clots). It is especially risky for patients with underlying conditions such as hyperviscosity syndrome, multiple myeloma, or waldenström macroglobulinemia.
- Infusion Reactions: Infusion-related reactions such as fever, chills, headache, and muscle pain may occur. Close monitoring is necessary during the infusion, and in the event of an adverse reaction, the infusion rate should be reduced or temporarily stopped.
- Maltose Considerations: Maltose is a sugar, and its presence in this formulation can interfere with blood glucose monitoring, potentially giving falsely high readings. Patients with diabetes should ensure they use glucose measurements that are unaffected by maltose.
- Vaccination Interference: After receiving Immunoglobulin-G with maltose, there may be interference with live vaccines. It's generally recommended to wait at least 3 months after IVIG therapy before administering live vaccines like measles, mumps, or rubella.

Immunoglobulin-G Human + Maltose Indication - Uses and Benefits

Immunoglobulin-G Human + Maltose is indicated for various conditions, including both primary and secondary immunodeficiencies:

- Primary Immunodeficiency: This includes conditions like Common Variable Immunodeficiency (CVID), X-linked agammaglobulinemia, and other genetic defects in the immune system that cause frequent infections. The treatment provides passive immunity and enhances the body’s ability to fight infections.
- Autoimmune Diseases: It is used in autoimmune disorders such as Guillain-Barré Syndrome (GBS), immune thrombocytopenic purpura (ITP), myasthenia gravis, and others to modulate the immune system and reduce abnormal immune activity.
- Post-exposure Prophylaxis: Immunoglobulin-G can be used after exposure to hepatitis B, hepatitis A, varicella, or measles to provide passive immunity and prevent disease development.
- Hematological Conditions: It is indicated for use in disorders where antibody function is required to fight infections and control abnormal platelet counts or other hematologic imbalances.
- Organ Transplantation: Immunoglobulin-G helps to prevent transplant rejection by providing support to the immune system and minimizing the need for additional immunosuppressive therapy.

Immunoglobulin-G Human + Maltose Contraindications - Important Warnings

Certain conditions make Immunoglobulin-G Human + Maltose inappropriate for use. Contraindications include:

- Hypersensitivity: Contraindicated for patients who are allergic to IgG preparations or any components in the formulation, including maltose. This can lead to life-threatening reactions, such as anaphylaxis.
- IgA Deficiency: Individuals with IgA deficiency (a lack of immunoglobulin A) may experience severe hypersensitivity reactions due to the presence of trace amounts of IgA in the product. It should only be used in these patients if the benefits outweigh the risks.
- Severe Renal Insufficiency: The presence of maltose in the formulation requires caution in patients with severe renal impairment or those with a history of kidney disease, as these patients are more susceptible to kidney damage.
- Hyperviscosity Syndromes: Immunoglobulin-G with maltose should not be used in patients with hyperviscosity syndromes (such as waldenström macroglobulinemia or multiple myeloma) due to the risk of thromboembolic events (e.g., stroke, deep vein thrombosis).
- Active Infections: In cases of active infections or systemic inflammatory diseases, it may not be recommended until the infection is adequately treated or controlled.

Immunoglobulin-G Human + Maltose Side Effects - What to Expect

Common and serious side effects can occur with Immunoglobulin-G Human + Maltose. Key side effects include:

- Common Side Effects:
- Fever and Chills: Many patients experience fever or chills during or after the infusion.
- Headache: A frequent side effect, especially during or after administration.
- Fatigue: Some patients may feel unusually tired or fatigued following the infusion.
- Injection Site Reactions: Redness, swelling, or pain may occur at the site of injection.
- Serious Side Effects:
- Anaphylaxis: Rare but life-threatening allergic reactions, such as anaphylaxis, can occur. Signs include difficulty breathing, swelling of the throat, or rash.
- Renal Failure: High doses or rapid infusion can lead to acute renal failure in susceptible individuals, particularly those with underlying kidney disease.
- Thrombosis: The product can increase the risk of blood clots, leading to conditions like deep vein thrombosis (DVT) or pulmonary embolism (PE), particularly in patients with hyperviscosity or those who are immobile.
- Hemolysis: Destruction of red blood cells, leading to anemia, can occur in rare cases.
- Hyperviscosity: The product may cause increased blood viscosity, potentially resulting in stroke or other thrombotic complications.

Immunoglobulin-G Human + Maltose Pregnancy Category ID - Safety Information

3

Immunoglobulin-G Human + Maltose Mode of Action - How It Works

The Immunoglobulin-G Human + Maltose combination works by delivering passive immunity through a high concentration of immunoglobulin G (IgG) derived from pooled human plasma. The addition of maltose serves as a stabilizer for the immunoglobulin.

- Immunoglobulin G provides immediate passive immunity by supplying the body with antibodies against various pathogens. These antibodies help the body defend against infections by neutralizing viruses, bacteria, and toxins.
- Maltose in the formulation stabilizes the immunoglobulin and aids in the proper storage and administration of the product.
- Immune Modulation: The therapy also modulates the immune system, helping to reduce the abnormal immune responses in autoimmune disorders like Guillain-Barré syndrome and immune thrombocytopenic purpura (ITP).

Immunoglobulin-G Human + Maltose Drug Interactions - What to Avoid

Immunoglobulin-G Human + Maltose may interact with other medications or conditions. Key interactions include:

- Blood Glucose Testing: The maltose component in the product can interfere with glucose meters, leading to false elevations in blood glucose readings. Patients with diabetes should ensure they are using glucose measurement systems not affected by maltose.
- Live Vaccines: Immunoglobulin-G with maltose may affect the immune response to live vaccines, such as those for measles, rubella, and yellow fever. It is advisable to delay live vaccine administration for at least 3 months after treatment.
- Anticoagulants and Antiplatelet Drugs: Patients using anticoagulants (e.g., warfarin) or antiplatelet drugs (e.g., aspirin) are at a higher risk for bleeding complications when receiving this therapy. Caution is required when combined with these medications.
- Immunosuppressive Drugs: Co-administration with immunosuppressive agents (e.g., corticosteroids, chemotherapy drugs) may alter the effectiveness of Immunoglobulin-G by suppressing the immune response. Careful monitoring and dose adjustments may be necessary.

Immunoglobulin-G Human + Maltose Adult Dose - Recommended Dosage

The dosing for Immunoglobulin-G Human + Maltose depends on the condition being treated and the patient’s response:

- Primary Immunodeficiency: Doses typically range from 300 to 600 mg/kg of body weight, administered every 3-4 weeks depending on individual clinical needs.
- Autoimmune Conditions: A typical dose for Guillain-Barré syndrome or ITP is about 1 g/kg of body weight administered for 1-2 days.
- Post-Exposure Prophylaxis: 0.6 mL/kg body weight as a single dose for post-exposure treatment in conditions like hepatitis B.

Immunoglobulin-G Human + Maltose Child Dose - Dosage for Children

The pediatric dose is often based on weight and condition:

- Primary Immunodeficiency: 200-400 mg/kg every 3-4 weeks, with adjustments based on clinical response.
- Autoimmune Conditions (e.g., ITP, Guillain-Barré Syndrome): The dose is typically 1g/kg for 1-2 days depending on severity.
- Post-Exposure Prophylaxis: 0.6 mL/kg for conditions like hepatitis or varicella exposure.

As always, healthcare consultation is crucial before starting treatment to determine appropriate dosing for pediatric patients.

Immunoglobulin-G Human + Maltose Renal Dose - Dosage for Kidney Conditions

For individuals with renal impairment, lower doses or slower infusion rates may be required, and close monitoring of kidney function is essential. The presence of maltose in the formulation adds an extra level of complexity, as it can contribute to renal failure in sensitive individuals.